Update on the treatment of osteoporosis

Formulary

Volumn 38, Issue 4, 2003, Pages 223-243

  Hisel, Tina M ^a   Phillips, Beth Bryles ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; CALTRATE 600; CALTRATE 600 D; CALTRATE PLUS WITH MINERALS; CITRACAL D; CITRACAL LIQUITAB; CITRATE CALCIUM; CONJUGATED ESTROGEN; CORTICOSTEROID; DIHYDROXYALUMINUM SODIUM CARBONATE; MEDROXYPROGESTERONE ACETATE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMS; TUMS 500; TUMS E X; TUMS ULTRA; VIACTIV CALCIUM CHEWS; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; BONE DENSITY; BONE MINERAL; BREAST CANCER; CALCIUM INTAKE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG FEVER; DUAL ENERGY X RAY ABSORPTIOMETRY; FLUSHING; FRACTURE; HEART INFARCTION; HOT FLUSH; HUMAN; MYALGIA; NAUSEA; NONHUMAN; OSTEOPOROSIS; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; VEIN THROMBOSIS; VITAMIN INTAKE; VOMITING;

EID: 0141959208     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
2. Iqbal MM. Osteoporosis: epidemiology, diagnosis, and treatment. South Med J 2000;93:2-18.
3. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Excerpta Medica, Inc.; 1998.
4. Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997;102:35S-39S.
5. Ross PD. Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am 1998;27:289-301.
6. Amin S, Felson DT. Osteoporosis in men. Rheum Dis Clin North Am 2001;27:19-47.
7. Cummings SR, Bates DB, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97.
8. Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996;11:1961-6.
9. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-42.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized clinical trial. JAMA 2002;288:213-33.
11. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
12. Chestnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000;109:267-76.
13. Overgaard K, Hanse MA, Jensen SB, Christiansen C. Effects of salmon calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
14. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
15. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
16. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43.
17. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
18. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.
19. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis: a randomized controlled trial. Osteoporos Int 2000;11:83-91.
20. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
21. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
22. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994;272:1942-8.
23. Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in post-menopausal women: clinical guidelines. Clin Ther 1999;21:1025-44.
24. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
25. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3.
26. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
27. Johnston CC Jr, Bjamason NH, Cohen FJ, et al. Long-term effects ofraloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-50.
28. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
29. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol 2001;88:392-5.
30. Evista (raloxifene) [Package insert]. Indianapolis, IN: Eli Lilly and Co;2001 (revised).
31. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of post-menopausal osteoporosis. Osteoporos Int 2001;12:140-51.
32. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997;103:468-76.
33. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24.
34. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Interventioin Study Group. N Engl J Med 1998;339:292-9.
35. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
36. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15:1006-13.
37. Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002;47:1665-78.
38. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119:631-8.
39. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95:3112-17.
40. Schnitzer T, Bone HG, Crepaldi S, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000;12:1-12.
41. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11.
42. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
43. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205-9.
44. Forteo (teriparatide) [package insert]. Indianapolis, IN: Eli Lilly and Co; 2002.
45. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in post-menopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000;85:720-6.
46. Tiras MB, Noyan V, Yildiz A, et al. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 2000;15:2087-92.
47. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076-81.
48. Johnell O, Scheele WM, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92.
49. Trovas GP, Lyritis GP, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002;17:521-7.